Breakthrough AI-Designed COVID-19 Drug Enters Clinical Trials
Insilico Medicine, an AI-driven biotech company based in Hong Kong and New York City, has announced the initiation of Phase I clinical trials for its groundbreaking AI-designed COVID-19 drug. Unlike vaccines, this oral therapeutic aims to treat COVID-19 symptoms directly. If approved, it could revolutionize the fight against the virus, becoming the first-ever alternative to Paxlovid, the only existing COVID-19 medication . Power of generative AI Insilico Medicine’s CEO, Alex Zhavoronkov, Ph.D., emphasized the transformative power of generative AI in various fields, including drug development. The company’s newly unveiled molecule, ISM3312, has demonstrated exceptional effectiveness against COVID-19 variants, even those resistant to Paxlovid, while offering improved stability and prolonged efficacy. Paxlovid has been linked to undesirable side effects, including “Paxlovid rebound,” where patients who initially test negative for COVID-19 later test positive again, and “Paxlovid mou...